Our modular bioconjugation platform allows for the rapid and optimal design of a drug conjugate. The diversity of our targeting moieties, linkers, and payloads enables a tailored design to match the specific requirements of the target biology.
Designing Bespoke Therapies
Partner With Us to Develop
Solutions to Your ADC Challenges
Our platform provides flexibility in targeting different types of cancer. It allows for different payloads (eg, enzyme inhibitors, immune activators, and cytotoxic agents), intra- and extracellularly cleavable linker designs and precise tuning of the physicochemical profile of the payload.
The range of possibilities is illustrated by the design of highly tumor cell-specific antibody-drug conjugates (ADCs) using our proprietary legumain-cleavable linker and the novel KSPi-CellTrapper™ payload, which is hydrophilic and accumulates in the tumor cell to achieve enhanced cytotoxicity. After tumor cell death, the payload is unable to enter healthy cells thus limiting the well-known toxicities of ADCs.
Our small molecule drug conjugates (SMDCs) with an elastase-cleavable linker and an optimized camptothecin as payloads are designed for warhead release in the tumor microenvironment to maximize killing of the tumor and its supporting cells while limiting unwanted toxicities.
Developing Solutions to the ADC Problems
Our small molecule drug conjugates (SMDCs) with an elastase-cleavable linker and an optimized camptothecin as payloads are designed for warhead release in the tumor microenvironment to maximize killing of the tumor and its supporting cells while limiting unwanted toxicities.
Developing Solutions to the ADC Problems
Highly specific binding to the target
Internalization of the ADC and trafficking to the lysosome. Specific cleavage by legumain
Release of the payload and inhibition and of kinesin spindle protein (KSP)
CellTrapper™ modified payload is hydrophilic and accumulates in the tumor cell for improved safety and tolerability for long-term therapy and targeting leukemic stem cells
Highly specific binding to the target
Internalization of the ADC and trafficking to the lysosome. Specific cleavage by legumain
Release of the payload and inhibition and of kinesin spindle protein (KSP)
CellTrapper™ modified payload is hydrophilic and accumulates in the tumor cell for improved safety and tolerability for long-term therapy and targeting leukemic stem cells
WHY PARTNER WITH US?
State of the art technologies to advance next-generation ADCs:
- Management team with a proven track record of successful drug development including bioconjugation technologies
- A diverse array of proprietary modular bioconjugation technologies to develop an optimal therapeutic match to address individual aspects of target biology
- Legumain-cleavable linker and CellTrapper™ technologies cooperate and allow for a specific payload release and accumulation inside the tumor cell, thus increasing efficacy and minimizing side effects
- Together we can meet your ADC challenges with people, technologies, and a collaborative license-ready approach to drug design and development